We report a rare case of phaehyphomycosis in a 71-year-old heart transplant recipient Togo native patient. Four months after the transplant, he presented painless nodules on the right heel with superficial ulceration. The polyphasic identification uncovered a rare cause of phaehyphomycose: V. botryosa. The treatment combined surgical excision of the lesions and anti-fungal therapy with posaconazole. We discussed eleven reported cases in literature since 1990.
Introduction
Infectious complications, especially fungal, are common in transplant recipients due to the underlying immunosuppression. We report a rare case of phaehyphomycosis Veronaea (V.) botryosa in a heart transplant recipient. The originality of this phaehyphomycosis is the rarity of the species identified. In the literature, 11 other cases of V. botryosa-induced cutaneous phaeohyphomycosis have been reported since 1990 including 3 cases in transplant recipients. This case highlighted the importance of careful research of fungal infection in immunocompromised transplant recipients and monitoring of the immunosuppressive regimen.
Case
A 71 year old native Togo patient, who has been living in France since 1970 and has not been back to Africa for 20 years, also a heart transplant recipient, was hospitalized for nodules on his right heel. The nodules were painless and slowly progressive with superficial ulceration (1A and 1B). His significant medical history included hypertension, insulin-dependent diabetes mellitus, and ventricular tachycardia with implantable defibrillator. He had a history of hypertrophic cardiomyopathy that required a heart transplantation on May 2014 (day 1), and was complicated by several bacterial infections (Enterobacter cloacae, Enterococcus faecalis, Pseudomonas aeruginosa), fungal infections (Fusarium sp. ascites), and a postoperative CMV reactivation. His immunosuppressive treatment included mycopheno- The isolate was sent to the National Reference Center for Invasive Mycoses and Antifungals (NRCMA), Institut Pasteur, Paris, for speciation. The microscopic examination of a velvety blackish-brown colony on 2% malt agar (MEA), revealed straight to flexuous, smooth-walled melanized conidiophores (2A and 2B). Conidiogenous cells were mostly terminal, bearing 1-septate smooth-walled cylindrical conidia truncated at the base. On the basis of its morphological features, the filamentous fungus was identified as Veronaea botryosa. Molecular confirmation was ascertained by the amplification and sequencing of the ITS1-5.8S-ITS2 region of the ribosomal DNA [1] . Comparison of the nucleotide sequence of the isolate (623 bp) with GenBank database showed a 99.8% identity (623/622) with V. botryosa type strain CBS 254.57 (GenBank NR_103593.1).
Due to the immunodeficiency of the patient, a staging was performed (PET scan and brain imaging) which returned normal. Lymphopenia (210/ mm3) was noted in the blood test. The treatment included surgical excision of the lesions and anti-fungal therapy with posaconazole 400 mg twice a day for 3 months. The evolution of the lesions was favorable, but a few months later (day 330), the patient died from septic shock (Klebsiella pneumonia and Escherichia coli septicemia) (Figs. 1 and 2 ).
Discussion
Phaehyphomycosis is defined by the presence of melanized yeastlike cells or hyphae in tissues. Patients diagnosed with phaeohyphomycosis are often immunocompromised (diabetics, transplant recipients, patients on immunosuppressive drugs or steroids). These fungi induce subcutaneous and systemic opportunistic and cosmopolitan infections [2] . They are saprophyte of plants, water, and earth. Their transmission mode is land-based, through contaminated water or vegetable items. The melanin present in the cell wall is a known virulence factor. The physiopathology of the infection remains unclear, but some authors speculate that the organism is acquired previously, remained quiescent, and is reactivated due to immunosuppression [3] . [4] , The uniqueness of this phaehyphomycosis case is that the species found is extremely rare. To date, only 11 cases of V. botryosa-induced cutaneous phaeohyphomycosis have been reported since 1990. We report here the main characteristics of these patients (Table 1) : most patients were natives from Asia, the mean (age: 51,7 years old, and most of them were males (8 men/12 cases with our case). This is the third reported case of V. botryosa infection in a transplant-recipient. The clinical presentation was papulo-nodules or ulcerations, mainly on the lower limbs. All patients were treated by anti-fungals and four with surgery leading to a favorable outcome with resolution of the lesions for 7 patients.
V. botryosa can induce both chromoblastomycosis (chronic disease of the skin and subcutaneous tissues in tropical regions characterized by the presence of fumagoid cells and phaeohyphomycosis). The clinical presentation of phaehyphomycosis is polymorphic (only skin involvement, systemic, superficial, or deep infection). It requires both histopathological and mycological analysis. Histological diagnostic criteria include the presence of brown hyphae, septate vesicular thickened wall to dark brown accompanied by yeast-like elements poorly systematized in an inflammatory granuloma. The cell wall is pigmented and stained by Gomori Grocott. Histology displays a cystic abscess with granulomatous reaction. Identification of the species involved is essential since many different species can be responsible for phaeohyphomycosis. Lack of sporulation for the isolate prevented antifungal susceptibility testing. However, previous studies have shown that the species usually exhibits high minimal inhibitory concentrations (MIC) of amphotericin B, terbinafine, voriconazole and echinocandins with lower MICs of itraconazole and posaconazole [5] . The patient was thus prescribed posaconazole together with surgical resection of the lesion. Most of the cases reported were only prescribed antifungal drugs. Phaeohyphomycosis should be kept in mind in transplant recipients. 
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